124
Participants
Start Date
November 30, 2005
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
CPOP-R
Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
CHOP-R
Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
St. Luke's Roosevelt Hospital, New York
Jacobi Medical Center Phase I Oncology, The Bronx
Our Lady of Mercy Medical Center, The Bronx
Interlake Foundation, Inc., Rochester
Berks Hematology-Oncology Associates Ltd., Reading
Center for Cancer and Blood Disorders, P.C., Bethesda
Greater Baltimore Medical Center, Baltimore
Maryland Hematology/Oncology Associates, PA, Baltimore
Frederick Memorial Hospital Cancer Center, Frederick
Duke University Medical Center, Durham
Brody School of Medicine at East Carolina University - Leo W. Jenkins Cancer Center, Greenville
Charleston Cancer Center, Charleston
Low County Hematology & Oncology, Mt. Pleasant
Farmacia Osepdaliera, Odpedale Umberto I, Mestre
John B. Amos Cancer Center, Columbus
Memorial Cancer Institute, Pembroke Pines
Ospedale Civile, Udine
Broward Oncology Associates, Fort Lauderdale
Oncology Hematology Associates of West Broward, Tamarac
The Center of Hematology and Oncology, Boca Raton
Hematology Oncology Specialists, Tampa
Watson Clinic for Cancer Care and Research, Lakeland
Watson Clinic, Lakeland
Osceola Cancer Center, Kissimmee
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie
Sarah Cannon Cancer Center, Nashville
Thompson Cancer Survival Center, Knoxville
The Family Cancer Center, Collierville
North Missssppi Hematology Oncology Associates, Tupelo
Columbus Clinic, Columbus
"Instituto di Ematologia Lorenzo e Ariosto", Bologna
Consultants in Blood Disorders and Cancer, Louisville
Universitaetsklinikum Duesseldorf, Düsseldorf
Western Kentucky Hematology/Oncology Group, Paducah
CHU Hotel Dieu, Nantes
Barberton Citizen's Hospital, Barberton
Summa Health Systems Hospitals, Akron
Oncology Partners Network, Cincinnati
Dayton Clinical Oncology Program, Dayton
Cancer Care Center, New Albany
Azienda Ospedaliera Careggi, Florence
Klinikum der Universitaet zu Koeln, Cologne
Policlinico S. Maria alle Scotte, Siena
Hubert H Humphrey Cancer Center, Robbinsdale
Cancer Treatment & Research Mid-Dakota Clinic, Bismarck
Oncology Hematology of Northern Illinois, Gurnee
Mid-Illinois Hematology & Oncology Associates, Normal
Capital Comprehensive Cancer Care, Jefferson City
Hopitaux Universitaires de Strabourg - Hopital Hautepierre, Strasbourg
Southeast Nebraska Hematology and Oncology Consultants, P.C., Lincoln
Our Lady of the Lake Regional Medial Center, Hematology Oncology, Baton Rouge
Texas Hematology Oncology Center, Dallas
The Center for Cancer and Blood Disorders, Fort Worth
Southwest Regional Cancer Center, Austin
Rocky Mountain Cancer Center, Denver
Northern Utah Hematology Oncology, P.C., Ogden
New Mexico Hematology/Oncology Consultants, Albuquerque
Nevada Cancer Institute, Las Vegas
Ospedal V. Cervello, Palermo
Klinikum Nurnberg Nord - Medizinische, Nuremberg
UCSD Moore's Cancer Center-Blood & Marrow Transplantation Division, La Jolla
Sharp Memorial Hospital, San Diego
Loma Linda University Medical Center, Loma Linda
Hematology/Oncology Group of Orange County, Orange
Bay Medical Oncology & Hematology, Concord
Hazel Hawkins Hospital, Dept. of Medical Oncology, Hollister
Universitaetsklinikum Wuerzburg, Würzburg
Northwest Kaiser Permanente, Portland
Multicare Oncology Hematology Specialists, Tacoma
Tufts-New England Medical Center-The Neely Ctr for Clinical Cancer Research, Boston
London Health Science Center Regional Care Program, London
The Ottawa Hospital, Ottawa
Queen Elizabeth II HSC, Halifax
Universitaetsklinikum Carl Gustav Carus, Dresden
Uiversita La Sapienza, Roma
Lead Sponsor
CTI BioPharma
INDUSTRY